Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Instil Bio, Inc. (TIL)

Instil Bio Q1 2026 net loss narrows to $4.2 million from $28.2 million

Positive Impact 3 of 5 earnings Written later

Instil Bio reported a first quarter 2026 net loss of $4.2 million, or $0.62 per share, compared with a net loss of $28.2 million, or $4.32 per share, a year earlier. The company also said it is evaluating potential acquisitions and in-licensing deals, though it gave no assurance any transaction will occur.

Key points

  • Q1 2026 net loss was $4.2 million ($0.62 per share) versus $28.2 million ($4.32 per share) in Q1 2025.
  • Research and development expenses fell to $0.7 million from $5.4 million, and restructuring and impairment charges fell to $1.0 million from $16.1 million.
  • Cash, cash equivalents, restricted cash and marketable securities totaled $74.7 million at March 31, 2026, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.

The filing

CompanyInstil Bio, Inc. (TIL)
Form8-K, current report
Filed with the SECMay 15, 2026, 8:30 AM ET
Accession number0001789769-26-000044

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.